RxDoctor Payments Data

Brian Williams, PA

Physician Assistant · Porterville, CANPI 1598701914

Payments from drug & device makers

$2,854in general payments, 2019–2025

Across 133 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$479
  • Lilly USA, LLC$366
  • Otsuka America Pharmaceutical, Inc.$274
  • AstraZeneca$235
  • Astellas Pharma US Inc$202
  • Axsome Therapeutics, Inc.$167
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,76097%
  • Education$943%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,854 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$44,908
Medicare patients
264
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide13$14,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,494
JardianceEmpagliflozin11$13,196
Albuterol Sulfate HfaAlbuterol Sulfate18$1,046
Trazodone Hcl62$387
Levothyroxine Sodium47$341
Atorvastatin Calcium28$323
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$311
Dicyclomine Hcl13$289
Azithromycin67$265
Diclofenac Sodium13$251
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$206
Omeprazole19$195
Metoprolol Succinate11$192
Lisinopril25$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$366$14,84713 claims
GSKTrelegy Ellipta$30$14,49416 claims
Boehringer IngelheimJardiance$66$13,19611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Porterville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →